Search

News The Importance of Proper Protein and Calorie Intake in Critically Ill Patients –⁠ Insights from Recent Comparisons

The issue of nutrition, especially proteins, is a crucial aspect affecting the overall health and prognosis of critically ill patients. Two recent studies published in the journals Critical Care and Journal of Parenteral and Enteral Nutrition focused on nutrient intake.

Source: Parenteral Nutrition 14. 11. 2022

News Biological treatment of psoriatic arthritis in the 1st line –⁠ results of the SPIRIT-H2H study after 1 year of follow-up

The SPIRIT-H2H study compared the efficacy of ixekizumab and adalimumab, either as monotherapy or with concomitant methotrexate (MTX), in patients with psoriatic arthritis (PsA) who had not been previously treated with biologics. The results of the recent work presented below after one year of follow-up suggest that the efficacy of ixekizumab remains the same regardless of the use of MTX, while the efficacy of adalimumab increases in combination with MTX.

Source: Biological Treatment 3. 5. 2021

News Ceftaroline as a Treatment Option for MRSA-Induced Sepsis?

A recently published study by a team of authors from several American institutions focused on comparing the efficacy and safety of the 5th generation cephalosporin ceftaroline with the standard of care in the treatment of sepsis caused by methicillin-resistant Staphylococcus aureus (MRSA).

Source: Anti-Infectives 16. 9. 2022

News EMA Approved Empagliflozin for the Treatment of Heart Failure Regardless of Left Ventricular Ejection Fraction

Prague, March 8, 2022 –⁠ Hundreds of thousands of patients in the Czech Republic can soon look forward to a treatment that may positively influence the progression of their disease. The European Medicines Agency (EMA) approved the registration of Jardiance® (empagliflozin) for the treatment of adults with symptomatic chronic heart failure with preserved left ventricular ejection fraction at the beginning of March. It thus becomes the first drug that doctors can prescribe to all patients, regardless of ejection fraction status. EMA had previously approved empagliflozin for the treatment of patients with chronic heart failure with reduced ejection fraction and for the treatment of adults with inadequately controlled type 2 diabetes. The drug was developed by Boehringer Ingelheim.

Source: Heart Failure 8. 3. 2022

News Long-term Safety of Dupilumab in Adult Patients with Moderate to Severe Atopic Dermatitis

Moderate to severe atopic dermatitis (AD) often requires systemic therapy. The long-term safety of dupilumab in patients with this condition was evaluated in an open-label extension (OLE) of the LIBERTY AD study, the results of which were recently published.

Source: Systemic treatment of atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis – Type 2 inflammation 24. 1. 2023

News Idiopathic Thrombocytopenic Purpura with SARS-CoV-2 Infection

To date, 45 cases of idiopathic (autoimmune) thrombocytopenic purpura (ITP) in individuals with confirmed SARS-CoV-2 infection have been published in the literature. In September 2020, a review summarizing the clinical profile and treatment outcomes of ITP in these individuals was released.

Source: Immune Thrombocytopenia 27. 10. 2020

News Current View on Obstacles in Proper Use of Antibiotics and the Role of Biomarkers in Infection Diagnosis

In the fight against antibiotic resistance, principles for the proper use of antibiotics (ATB) have been introduced globally. The following overview briefly describes the obstacles in leading rational antibiotic therapy and considers the use and benefits of biomarkers.

Source: Anti-Infectives 13. 4. 2023

News Educational Quiz (For Downtime)

The following quiz has been prepared for you as an activity for relaxation and unwinding from today's hectic days. In an easy manner, it will refresh your knowledge about immune cells and may even offer some education or entertainment.

Source: Systemic treatment of atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis – Type 2 inflammation 20. 4. 2020

News Perioperative Management in Patients with Atrial Fibrillation Treated with NOACs

The recommended procedures for perioperative management in patients using novel oral anticoagulants (NOACs) stem from the requirement to minimize treatment interruption before and after surgical procedures to reduce the risk of bleeding and thromboembolism. The safety of these regimens in patients with atrial fibrillation was examined in the prospective PAUSE study presented below.

Source: Anticoagulant Treatment 27. 5. 2020

News Reasons for Nonadherence to Statin Therapy -⁠ Survey Results Among Patients

Adherence to statin therapy remains suboptimal despite its proven benefits in reducing cardiovascular risk in individuals with dyslipidemia. Recently published survey results conducted among patients prescribed statins have identified barriers preventing proper adherence to this treatment.

Source: Cardiovascular Risks 23. 3. 2021

News Quantitative CT as a New Tool for Evaluating COPD in Alpha-1 Antitrypsin Deficiency

For such a rare hereditary disorder as alpha-1 antitrypsin deficiency (AATD), we have so far used functional tests as the main tool for monitoring the progression of lung disease. Now we are moving further. Quantitative CT examination is even more advantageous in terms of assessing clinical development.

Source: Deficiency of Alpha-1-Antitrypsin 18. 2. 2021

Články časopisu Importance of early diagnostics of inherited metabolic disorders in neonatal age

Author of the article: M. Magner, P. Ješina, P. Klement, D. Lorenčík, V. Vobruba, J. Zeman, T. Honzík Source: Česko-slovenská pediatrie | 1/2013 6. 2. 2013

Články časopisu Laparoscopic gastric plication in the treatment of obesity and metabolic disorders: 10-years results

Author of the article: Karin Doležalová, Petra Šrámková, Martin Fried Source: Časopis lékařů českých | 3-4/2020 31. 7. 2020

News Lung Recovery After COVID-19: How Reversible is the Damage?

During the virtual XXV Hradec Pulmonology Days held in April 2021, various aspects concerning COVID-19 were among the major topics. Dr. Bram van den Borst from Radboud University Nijmegen provided a comprehensive summary of current insights regarding lung recovery following an infection.

Source: COPD 22. 6. 2021

News Debate on Sepsis Biomarkers 'on Blood'

Sepsis represents a major cause of death from infectious diseases. Early identification of patients with a prognosis of sepsis is therefore crucial for their survival and prognosis. In addition to traditional biomarkers such as C-reactive protein (CRP) or procalcitonin (PCT), other markers are being sought that could be used in the differential diagnosis of sepsis. This issue was also addressed at a symposium organized by Beckmann Coulter, which took place on April 28, 2022, as part of the Colours of Sepsis congress in Ostrava.

Source: Because 16. 5. 2022